ABRIANA GAUL: Open Payments
NPI 1821647884 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$347 in 17 payments from 8 companies in 2025. Trend: 2023 $436 · 2024 $214 · 2025 $347
Food & beverage: $347
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 4 | $109 |
| Amgen Inc. | 4 | $67 |
| Novartis Pharmaceuticals Corporation | 2 | $45 |
| ACADIA Pharmaceuticals Inc | 2 | $39 |
| Biogen, Inc. | 2 | $32 |
| CSL Behring | 1 | $22 |
| Chiesi USA, Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $15 |
Products named: FABRAZYME, Repatha, LEQVIO, NUPLAZID, TYSABRI, Hizentra, CLEVIPREX, Gamunex-C.
Industry payments across TX — which companies pay providers there.
